Vascular endothelial growth factor: The key mediator in pleural effusion formation

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 4, 2002, Pages 294-301

  Grove, Carolyn S ^a   Lee, Y C Gary ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; DISEASE ASSOCIATION; HYPOXIA; MOUSE; NONHUMAN; OVARY DISEASE; PLEURA CAVITY; PLEURA EFFUSION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; STAPHYLOCOCCUS AUREUS;

EID: 0036286548     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200207000-00009     Document Type: Review

References (84)

1. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia
2. Malignant pleural effusion: Would the real cause please stand up?
3. Pleurodesis for recurrent pleural effusions in the new millennium
4. Molecular and biological properties of vascular endothelial growth factor
5. VEGF: An update on biological and therapeutic aspects
6. Vascular endothelial growth factor and its receptors
7. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor
8. Vascular endothelial growth factor: Basic biology and clinical implications
9. The splice variants of vascular endothelial growth factor (VEGF) and their receptors
10. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors
11. Bacterial induction of pleural mesothelial monolayer barrier dysfunction
12. Role of the Fit-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
13. Vascular permeability factor/vascular endothelial growth factors: A multifunctional angiogenic cytokine
14. The role of VEGF and thrombospondins in skin angiogenesis
15. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries
16. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor
17. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells
18. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin
19. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A
20. The neuropilins: Multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis
21. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family
22. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity
23. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions
24. The vascular endothelial growth factor (VEGF) signaling pathway: A therapeutic target in patients with hematologic malignancies
25. Vascular endothelial growth factor in pleural fluid
26. Vascular Endothelial Growth Factor level correlates with Transforming Growth Factor beta isoform levels in pleural effusions
27. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer
28. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions
29. Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation
30. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
31. Vascular endothelial growth factor levels in pleural and peritoneal fluid in Meigs' syndrome
32. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
33. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma
34. Clinical implications of circulating angiogenic factors in cancer patients
35. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease
36. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions
37. Transforming growth factor-β induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro
38. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas
39. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer
40. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor
41. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance
42. Early expression of angiogenesis factors in acute myocardial ischemia and infarction
43. Focal angiogenic therapy for myocardial ischemia
44. The many faces of transforming growth factor beta in pleural diseases
45. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells
46. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1
47. TGF beta-1 regulation of VEGF production by breast cancer cells
48. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia
49. Aggregating human platelets stimulate expression of vascular endothelial growth factor in cultured vascular smooth muscle cells through a synergistic effect of transforming growth factor-beta 1 and platelet-derived growth factor AB
50. Mechanism of transforming growth factor-beta-1-induced expression of vascular endothelial growth factor in murine osteoblastic MC3T3-E1 cells
51. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-β isoforms in human glioma cells in vitro
52. Vascular endothelial growth factor: A jack of all trades or a nonspecific stress gene?
53. Acidosis inhibits endothelial cell apoptosis and function and induces basic fibroblast growth factor and vascular endothelial growth factor expression
54. Augmentation of cytokine-induced nitric oxide synthesis by hydrogen peroxide
55. Interleukin 6 induces the expression of vascular endothelial growth factor
56. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate
57. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I
58. Stimulatory and synergistic effects of luteinising hormone and insulin like growth factor 1 on the secretion of vascular endothelial growth factor and progesterone of cultured bovine granulosa cells
59. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1
60. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids
61. Mechanisms of fibroblast growth factor-2 modulation of vascular endothelial growth factor expression by osteoblastic cells
62. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells
63. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells
64. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice
65. Inhibition of vascular endothelial growth factor in the treatment of solid tumors
66. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation
67. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization
68. VEGF/FIk-1 interaction, a requirement for malignant ascites recurrence
69. The vascular endothelial growth factor receptor KDR/FIk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model
70. Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas
71. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody
72. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema
73. Gene delivery to the pleural space with systemic distribution of the gene product
74. Transforming growth factor-beta1 modulates the expression of vascular endothelial growth factor by osteoblasts
75. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
76. The effects of recombinant human monoclonal antibodies against vascular endothelial growth factor on malignant pleural effusions in patients with non-small cell lung carcinoma
77. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor
78. The role of cyclooxygenase-2 in prostate cancer
79. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation
80. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients
81. Angiogenesis and remodeling of airway vasculature in chronic inflammation
82. HIF-1: Using two hands to flip the angiogenic switch
83. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels